Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosfomycin vs Ciprofloxacin for Febrile Neutropenia Prevention
NCT05311254Phase 3Unknown
- Sponsor
- FINBA
- Start
- Mar 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fosfomycin in febrile neutropenia (FN), sponsored by FINBA. Primary endpoint: Febrile neutropenia of infectious origin at 60 days. Status: unknown.
02
Drugs
fosfomycin
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT05311254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05311254.